Biotechnology Value Screen Names Three Undervalued Stocks for April 2
April 2 biotech value screen names Bicycle Therapeutics, Novavax, and PTC Therapeutics. Novavax earned an A Value Grade; February screens included Arcturus, Emergent, Puma, Rigel, and Sutro.
Three undervalued biotechnology stocks were identified for Thursday, April 02, 2026, based on key financial metrics such as the price-to-sales ratio, shareholder yield, and the price-earnings ratio. The stocks making the list for top value stocks in the Biotechnology industry were Bicycle Therapeutics plc, Novavax, Inc., and PTC Therapeutics, Inc.
Similar screens run in February 2026 produced lists of five or six stocks with overlapping names. Novavax received a Value Grade of A on the April 2, February 24, and February 20 screens, while most other stocks received a B grade.
The April 2 screen scored the stocks as follows:
- Bicycle Therapeutics plc (BCYC): Price/Sales 4.67, Price/Earnings na, EV/EBITDA 0.4, Shareholder Yield (0.5%), Price/Book Value 0.56, Price/Free Cash Flow na, Value Grade B.
- Novavax, Inc. (NVAX): Price/Sales 1.15, Price/Earnings 3.1, EV/EBITDA 1.4, Shareholder Yield (1.4%), Price/Book Value na, Price/Free Cash Flow na, Value Grade A.
- PTC Therapeutics, Inc. (PTCT): Price/Sales 3.14, Price/Earnings 8.8, EV/EBITDA 6.7, Shareholder Yield (4.5%), Price/Book Value na, Price/Free Cash Flow 7.8, Value Grade B.
The February 24 screen listed Arcturus Therapeutics Holdings Inc., Novavax, Puma Biotechnology, Inc., Rigel Pharmaceuticals, Inc., and Sutro Biopharma, Inc. The February 20 screen listed Arcturus, Emergent BioSolutions Inc., Novavax, Rigel, and Sutro. The February 19 screen listed Arcturus, Emergent, Puma, PTC, Rigel, and Sutro.
The Value Grade is assigned based on how each stock's composite valuation compares to all other stocks. The process starts with percentile rankings for each valid valuation ratio, which are averaged and then ranked into quintiles from the cheapest 20% (a grade of A) to the most expensive 20% (a grade of F). A minimum of two valid variables are required for a Value Score.
Value investors seek to buy stocks at a discount to their intrinsic value, and long-term returns show that such strategies are advantageous. Value stocks, as a group, tend to outperform growth stocks over extended periods of time. Typically, value investors perform financial analysis of numerous metrics, don't follow the herd, and are long-term investors.
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.